A recent study showed that a low sPD-1/sPD-L1 ratio at baseline was associated with a shorter OS in comparison with a high sPD-1/sPD-L1 ratio in patients with advanced melanoma treated with nivolumab or pembrolizumab (33), consistent with our present results. Here, SPDL1 is linked to melanoma.